HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BI 2536

polo-like kinase 1 inhibitor
Also Known As:
BI-2536; BI2536
Networked: 106 relevant articles (10 outcomes, 32 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Munzert, Gerd: 10 articles (01/2017 - 12/2008)
2. Fritsch, Holger: 7 articles (01/2017 - 07/2010)
3. Liu, Xiaoqi: 4 articles (10/2021 - 01/2015)
4. Diensthuber, Marc: 4 articles (03/2013 - 07/2012)
5. Stöver, Timo: 4 articles (03/2013 - 07/2012)
6. Wagenblast, Jens: 4 articles (03/2013 - 07/2012)
7. Ahmad, Nihal: 3 articles (02/2022 - 01/2015)
8. Gaschler-Markefski, Birgit: 3 articles (01/2017 - 07/2010)
9. Li, Jie: 3 articles (01/2017 - 05/2015)
10. Strebhardt, Klaus: 3 articles (12/2015 - 05/2014)

Related Diseases

1. Neoplasms (Cancer)
2. Squamous Cell Carcinoma of Head and Neck
3. Lung Neoplasms (Lung Cancer)
10/02/2017 - "The combined regimen of BI-2536 (a Plk1 inhibitor) and fasudil (a ROCK inhibitor) promoted a significant inhibition of patient-derived lung cancer xenografts and prolonged the survival of LSL-KRASG12D mice. "
01/01/2017 - "Furthermore, disruption of WEE1 by CRISPR-Cas9 sensitized H322 lung cancer cells to AZD1775 to a similar extent as the potent PLK1 inhibitor BI-2536 suggesting a complex crosstalk between PLK1 and WEE1. "
02/28/2015 - "One of these compounds, the PLK1-specific inhibitor BI2536, has been investigated as a cytotoxic drug in several cancers, including lung cancer; however, the detailed mechanism by which BI2536 induces defects in cell proliferation of non-small cell lung cancer (NSCLC) has not yet been determined. "
01/01/2016 - "Co-administration of BI-2536 and fasudil either in the LSL-KRAS(G12D) mouse model or in a patient tumour explant mouse model of KRAS-mutant lung cancer suppresses tumour growth and significantly prolongs mouse survival, suggesting a strong synergy in vivo and a potential avenue for therapeutic treatment of KRAS-mutant cancers."
02/01/2012 - "In this study, we demonstrate that there is no obvious different cytotoxic response between cancer cells with and without functional p53, including the isogenic colon cancer cell lines HCT116p53(+/+) and HCT116p53(-/-), breast cancer cell line MCF7, lung cancer cell line A549 and cervical carcinoma cell line HeLa, after treatment with either siRNA against Plk1, the kinase domain inhibitors BI 2536 and BI 6727 or the PBD inhibitor Poloxin. "
4. Neuroblastoma
5. Hepatocellular Carcinoma (Hepatoma)

Related Drugs and Biologics

1. Phosphotransferases (Kinase)
2. Bortezomib (Velcade)
3. Proteins (Proteins, Gene)
4. Vorinostat
5. fasudil (AT 877)
6. Topotecan (Hycamtin)
7. NF-kappa B (NF-kB)
8. Messenger RNA (mRNA)
9. HhAntag691
10. Polo-Like Kinase 1

Related Therapies and Procedures

1. Therapeutics
2. Aftercare (After-Treatment)
3. Drug Therapy (Chemotherapy)
4. Stents
5. Radiotherapy